Browse > Article

Positron Emission Tomography with $^{18}F-FDG$ Fluorodeoxyglucose for Primary Lymphoma of Bone  

Kim, Nam-Don (Department of Interual Medicine, Korea Cancer Center Hospital)
Park, Yeon-Hee (Department of Interual Medicine, Korea Cancer Center Hospital)
Ki, Seung-Seog (Department of Interual Medicine, Korea Cancer Center Hospital)
Park, Yong-Jin (Department of Interual Medicine, Korea Cancer Center Hospital)
Kim, Heoyng-Joon (Department of Interual Medicine, Korea Cancer Center Hospital)
Ryoo, Baek-Yeol (Department of Interual Medicine, Korea Cancer Center Hospital)
Kim, Heung-Tae (Department of Interual Medicine, Korea Cancer Center Hospital)
Kim, Sung-Eun (Department of Nuclear Medicine, Korea Cancer Center Hospital)
Cheon, Gi-Jeong (Department of Nuclear Medicine, Korea Cancer Center Hospital)
Choi, Chang-Woon (Department of Nuclear Medicine, Korea Cancer Center Hospital)
Lim, Sang-Moo (Department of Nuclear Medicine, Korea Cancer Center Hospital)
Publication Information
The Korean Journal of Nuclear Medicine / v.37, no.5, 2003 , pp. 331-335 More about this Journal
Abstract
Purpose: Accurate assessment of the lesion after treatment of patients with bone lymphoma is difficult. In this patient who demonstrated complete remission after chemotherapy, the regions of fluorine-18 fluorodeoxyglucose $(^{18}FFDG)PET$ uptake diminished more rapidly fellowing therapy, indicating a complete response at much earlier stage than did Magnetic Resonance Imaging (MRI) or CT based findings. With the conventional methods, such as MRI and CT, It was difficult to assess whether the residual tumor tissue was viable or not. Decision to complete response is very important in patients with lymphoma to plan the further treatment. We experienced a patient with primary lymphoma of bone who revealed complete response to chemotherapy on $^{18}FFDGPET$ while CT showed persistent destructive bone lesion. Thus, $^{18}FFDGPET$ study after therapy may be superior to CT in the evaluation of response to treatment in primary lymphoma of bone.
Keywords
primary bone lymphoma; evaluation; FDG-PET;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Mulligan ME, McRae GA, Murphey MD. Imaging features of primary lymphoma of bone. AJR 1999;173: 1691-7   DOI   ScienceOn
2 Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001;115: 793-800   DOI   ScienceOn
3 Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jurgens H, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR 2001: 177:229-36
4 Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic value than classical computed tomography scan imaging. Blood 1999;94: 429-33   PUBMED
5 Dubey P, Ha CS, Besa PC, Fuller L, Cabanillas F, Murray J, et al. Localized primary malignant lymphoma of bone. Int J Radia Oncol Biol Phys 1997;37: 1087-93   DOI   ScienceOn
6 Durr HR, Muller PE, Hiller E, Maier M, Baur A, Jansson V, et al. Malignant lymphoma of bone. Arch Orthop Trauma Surg 2002;122: 10-6   DOI   PUBMED
7 Parker F, Jackson H Jr. Primary reticulum cell sarcoma of bone. Surg Gynecol Obstet 1939;68:43-5
8 Moog F, Kotzerke J, Reske SN. FDG PET can replace scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40:1407-13   PUBMED
9 Leeson MC, Makely JT, Carter JR, Krupco T. The use of radioisotope scans in the evaluation of primary lymphoma of bone. Orthop Rev 1989;18:410-6   PUBMED
10 Hicks DG, Gokan T, O'Keefe RJ, Totterman SM, Fultz PJ, Judkins AR, et al. Primary lymphoma of bone. Cancer 1995;75: 973-80   DOI   ScienceOn
11 Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Onco 2002;13: 1356-63   DOI   ScienceOn
12 Heyning FH, Hogendoorn PCW, Kramer MHH, Hermans J, Kluin-Nelemans JC, Noordijk EM, et al. Primary non-Hodgkin's lymphoma of bone: a clinicopathological investigation of 60 cases. Leukemia 1999;13: 2094-8   DOI   ScienceOn
13 Huvos AG. Primary non-Hodgkin's lymphoma of bone. In: Huvos AG. Bone tumor diagnosis, treatment, and prognosis. 2nd ed. Philadelphia: Saunders Co;1991, p. 625-37
14 Barr J, Burkes RL, Bell R, Blackstein ME, Fernandes B, Langer F. Primary non-Hodgkin's lymphoma of bone. Cancer 1994;73: 1194-9   DOI   ScienceOn
15 Romer W, Hanauske AR, Ziegler S, Thodtmann R, Weber W, Fuchs C, et al. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose.Blood 1998;91: 4464-71   PUBMED